Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Apoptosis evasion is crucial for malignant B-cell survival.
• Bcl-2 protein expression is implicated in this prolonged survival.
• Understanding bcl-2 expression patterns is key to B-cell malignancy research.

Purpose of the Study:

• To quantify bcl-2 protein levels during normal human B-cell maturation.
• To determine the frequency of aberrant bcl-2 expression in B-cell cancers.
• To identify specific B-cell malignancies associated with bcl-2 alterations.

Main Methods:

• Quantitative multiparametric flow cytometry was used.
• Bcl-2 expression was analyzed in normal bone marrow, peripheral blood, spleen, and lymph nodes.
• Neoplastic B cells from 144 patients were assessed for bcl-2 expression.

Main Results:

• Normal B-cell maturation shows low bcl-2 in precursors, high in mature lymphocytes, and very high in plasma cells.
• Mature B cells expressing lower CD23 levels had significantly higher bcl-2.
• Aberrant bcl-2 expression occurred in 66% of B-cell malignancies, mostly as overexpression (63%).
• Consistent bcl-2 overexpression was observed in follicular lymphoma with t(14;18) and MALT lymphoma.
• High bcl-2 overexpression rates were also noted in precursor B-acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia, and mantle cell lymphoma.

Conclusions:

• Bcl-2 expression varies significantly during normal B-cell development.
• Aberrant bcl-2 expression is a common feature in B-cell malignancies, indicating its oncogenic role.
• Specific B-cell lymphomas consistently overexpress bcl-2, highlighting its diagnostic and prognostic relevance.